SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, stock code on the main board of the Hong Kong …
Hua Medicine Announces 2021 Annual Results
SHANGHAI, CHINA, Mar 17, 2022 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK) today announces the audited annual results of …
Hua Medicine Announces 2020 Interim Results
SHANGHAI, CHINA, Aug 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the consolidated results of the …
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine’s Dorzagliatin Readying for NDA Submission
SHANGHAI, CHINA, Mar 19, 2021 – (ACN Newswire via SEAPRWire.com) – Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the audited annual results of …
Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin’s Phase III Combination with Metformin Trial
SHANGHAI, CHINA, Dec 18, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing …
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin
SHANGHAI, CHINA, Oct 14, 2020 – (ACN Newswire) – Hua Medicine (the “Company”, Stock Code: 2552.HK) announces that, after review and on-site verification under the …